Aura Biosciences Inc (AURA)
NASDAQ:AURA
Want to see AURA full AI Analyst Report?
Top Page
Aura Biosciences Inc
(NASDAQ:AURA)
Select Model
Select Model
Rating:48Neutral
Price Target:
$7.50
▲(2.88% Upside)
Action:ReiteratedDate:03/31/26
The score is primarily constrained by weak financial performance typical of a pre-revenue biotech—widening losses and increasing cash burn—despite a relatively low-debt balance sheet. Technical indicators are neutral-to-mildly constructive, but valuation support is limited by negative earnings and no dividend yield.
Positive Factors
Phase 3 progress
Accelerated Phase 3 enrollment and a clear topline timeline (2H2027) materially improve the probability of a pivotal outcome. Successfully completing a registrational trial is a durable fundamental milestone that advances regulatory pathway and potential commercialization for a first-line vision-preserving therapy.
Negative Factors
Pre-commercial / no revenue
Absence of product revenue through 2025 leaves the company fully dependent on external capital and milestone value creation. Without commercialization, there are no operating cash inflows to support margins or self-funding, increasing structural funding and execution risk over the medium term.
Read all positive and negative factors
Positive Factors
Negative Factors
Phase 3 progress
Accelerated Phase 3 enrollment and a clear topline timeline (2H2027) materially improve the probability of a pivotal outcome. Successfully completing a registrational trial is a durable fundamental milestone that advances regulatory pathway and potential commercialization for a first-line vision-preserving therapy.
Read all positive factors
Aura Biosciences Inc (AURA) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$432.06M
Dividend YieldN/A
Average Volume (3M)295.85K
Price to Earnings (P/E)―
Beta (1Y)1.50
Revenue GrowthN/A
EPS Growth-3.52%
CountryUS
Employees106
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.34
Shares Outstanding64,199,776
10 Day Avg. Volume355,322
30 Day Avg. Volume295,845
Financial Highlights & Ratios
PEG Ratio-5.42
Price to Book (P/B)2.40
Price to Sales (P/S)0.00
P/FCF Ratio-3.86
Enterprise Value/Market Cap0.90
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-3.60
Forecast
1Y Price Target
$20.67Price Target Upside183.49% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-1.82
Revenue Forecast (FY)N/A
Aura Biosciences Inc Business Overview & Revenue Model
Company Description
Aura Biosciences, Inc. operates as a biotechnology company that develops therapies to treat cancer. The company develops virus-like drug conjugates (VDC) technology platform for the treat tumors of high unmet need in ocular and urologic oncology. ...
How the Company Makes Money
null...
Aura Biosciences Inc Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
62
Positive
Cash Flow
22
Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | -1.29M | -1.18M | 0.00 |
| EBITDA | -111.66M | -94.89M | -83.70M | -59.12M | -34.42M |
| Net Income | -106.19M | -86.92M | -76.41M | -58.76M | -35.25M |
Balance Sheet | |||||
| Total Assets | 169.43M | 182.50M | 255.07M | 223.94M | 160.03M |
| Cash, Cash Equivalents and Short-Term Investments | 144.24M | 151.09M | 226.15M | 188.81M | 149.06M |
| Total Debt | 17.38M | 18.77M | 19.56M | 20.86M | 975.00K |
| Total Liabilities | 32.52M | 30.53M | 29.23M | 28.35M | 7.71M |
| Stockholders Equity | 136.91M | 151.97M | 225.85M | 195.58M | 152.31M |
Cash Flow | |||||
| Free Cash Flow | -85.19M | -81.06M | -64.56M | -55.70M | -34.53M |
| Operating Cash Flow | -84.74M | -79.81M | -63.85M | -54.60M | -32.41M |
| Investing Cash Flow | 35.59M | 68.82M | -113.96M | -67.87M | -2.13M |
| Financing Cash Flow | 77.16M | 1.59M | 97.29M | 95.63M | 166.26M |
Aura Biosciences Inc Technical Analysis
Positive
7.29
Price Trends
6.17
Positive
5.96
Positive
6.12
Positive
Market Momentum
0.27
Negative
70.94
Negative
83.15
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AURA, the sentiment is Positive. The current price of 7.29 is above the 20-day moving average (MA) of 6.69, above the 50-day MA of 6.17, and above the 200-day MA of 6.12, indicating a bullish trend. The MACD of 0.27 indicates Negative momentum. The RSI at 70.94 is Negative, neither overbought nor oversold. The STOCH value of 83.15 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for AURA.
Aura Biosciences Inc Risk Analysis
Aura Biosciences Inc disclosed 71 risk factors in its most recent earnings report. Aura Biosciences Inc reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Aura Biosciences Inc Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
62 Neutral | $986.20M | -9.27 | -32.72% | ― | ― | -20.34% | |
52 Neutral | $460.54M | -3.10 | -31.75% | ― | 230194.59% | 20.52% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | $181.87M | -0.64 | -115.95% | ― | 181.46% | -32.98% | |
49 Neutral | $957.17M | -4.03 | -101.33% | ― | ― | -34.16% | |
48 Neutral | $432.06M | -3.10 | -71.25% | ― | ― | -3.52% | |
45 Neutral | $418.45M | -62.28 | -5.63% | ― | 153.52% | 72.62% |
* Healthcare Sector Average
AURA
Aura Biosciences Inc
6.73
0.90
15.44%
ASMB
Assembly Biosciences
26.33
14.94
131.17%
KRRO
Korro Bio
12.61
-5.14
-28.96%
ANNX
Annexon Biosciences
5.89
4.03
216.67%
FDMT
4D Molecular Therapeutics
8.81
5.44
161.42%
DSGN
Design Therapeutics
15.79
10.93
224.90%
Aura Biosciences Inc Corporate Events
Business Operations and StrategyFinancial Disclosures
Aura Biosciences Reports 2025 Results, Advances Bel-Sar Pipeline
Positive
Mar 30, 2026
On March 30, 2026, Aura Biosciences reported fourth-quarter and full-year 2025 results, highlighting continued progress across its bel-sar oncology pipeline and solid financial resources. The company ended 2025 with $144.2 million in cash, cash eq...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.